Leerink Partnrs Estimates Atyr PHARMA Q2 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Atyr PHARMA in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings of ($0.17) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.55) EPS and FY2026 earnings at ($0.41) EPS.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02.

Several other research analysts have also recently commented on ATYR. Leerink Partners initiated coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Atyr PHARMA has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Trading Down 1.5%

NASDAQ ATYR opened at $3.29 on Monday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.66. The stock has a market capitalization of $292.82 million, a PE ratio of -3.50 and a beta of 0.79. The firm has a 50 day moving average of $3.27 and a two-hundred day moving average of $3.40.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Group One Trading LLC acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $26,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter valued at $36,000. Victory Capital Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter valued at $37,000. Raymond James Financial Inc. purchased a new stake in Atyr PHARMA in the 4th quarter valued at $39,000. Finally, XTX Topco Ltd purchased a new stake in Atyr PHARMA in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.